Company / Revenue per Share
Cytek Biosciences, Inc. Revenue per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$1.57
FY2025
5-year range
$0.02 / $2.97
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
#145 of 153
Health Care
What the data says
Among 153 Health Care companies, Cytek Biosciences, Inc. is in the bottom 5% for revenue per share. Revenue per Share has increased for 3 consecutive years, from $0.02 in FY2022 to $1.57 in FY2025.
Based on SEC 10-K filings.
1.57 in FY2025 with a 5-year CAGR of +135.2%.
Improved from $1.48 to $1.57 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +313.6%
- 5-Year CAGR
- +135.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 153This company $1.57 Sector average $124.28
▼
-98.7% below sector average
Key checks
Key Insights
- Cytek Biosciences, Inc.'s revenue per share has grown for 3 consecutive years.
- In FY2025, revenue per share increased 1.0% year-over-year.
- Ranks #145 out of 153 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.57 | +1.0% |
| FY2024 | $1.55 | +5.1% |
| FY2023 | $1.48 | +6565.4% |
| FY2022 | $0.02 | -99.3% |
| FY2021 | $2.97 | +13544.3% |
| FY2020 | $0.02 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026